News | November 13, 2024
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Subscribe To Our Newsletter & Stay Updated
